JP2023507848A5 - - Google Patents
Info
- Publication number
- JP2023507848A5 JP2023507848A5 JP2022538737A JP2022538737A JP2023507848A5 JP 2023507848 A5 JP2023507848 A5 JP 2023507848A5 JP 2022538737 A JP2022538737 A JP 2022538737A JP 2022538737 A JP2022538737 A JP 2022538737A JP 2023507848 A5 JP2023507848 A5 JP 2023507848A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- lag
- cdr
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025154757A JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952859P | 2019-12-23 | 2019-12-23 | |
| US201962952878P | 2019-12-23 | 2019-12-23 | |
| US62/952,859 | 2019-12-23 | ||
| US62/952,878 | 2019-12-23 | ||
| US202063019857P | 2020-05-04 | 2020-05-04 | |
| US63/019,857 | 2020-05-04 | ||
| US202063021556P | 2020-05-07 | 2020-05-07 | |
| US63/021,556 | 2020-05-07 | ||
| US202063031453P | 2020-05-28 | 2020-05-28 | |
| US63/031,453 | 2020-05-28 | ||
| US202063123581P | 2020-12-10 | 2020-12-10 | |
| US63/123,581 | 2020-12-10 | ||
| PCT/US2020/065873 WO2021133653A1 (en) | 2019-12-23 | 2020-12-18 | Therapy for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154757A Division JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507848A JP2023507848A (ja) | 2023-02-27 |
| JP2023507848A5 true JP2023507848A5 (https=) | 2023-12-21 |
Family
ID=76575359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538737A Pending JP2023507848A (ja) | 2019-12-23 | 2020-12-18 | 癌の治療のための療法 |
| JP2025154757A Pending JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154757A Pending JP2026001028A (ja) | 2019-12-23 | 2025-09-18 | 癌の治療のための療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230056230A1 (https=) |
| EP (1) | EP4081248A4 (https=) |
| JP (2) | JP2023507848A (https=) |
| KR (1) | KR20220119694A (https=) |
| CN (1) | CN114901306A (https=) |
| AU (1) | AU2020412595A1 (https=) |
| BR (1) | BR112022012437A2 (https=) |
| CA (1) | CA3165839A1 (https=) |
| IL (1) | IL294207A (https=) |
| MX (1) | MX2022007790A (https=) |
| TW (1) | TW202138387A (https=) |
| WO (1) | WO2021133653A1 (https=) |
| ZA (1) | ZA202206743B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295434A (en) * | 2020-02-21 | 2022-10-01 | Macrogenics Inc | cd137 binding molecules and their uses |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| WO2023279092A2 (en) * | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
| AU2022317820A1 (en) * | 2021-07-28 | 2023-12-14 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
| JP2024536881A (ja) * | 2021-09-29 | 2024-10-08 | 中山康方生物医▲藥▼有限公司 | 抗ｌａｇ３抗体、医薬組成物、及び使用 |
| WO2023066322A1 (zh) * | 2021-10-21 | 2023-04-27 | 杭州阿诺生物医药科技有限公司 | 一种融合多肽及其用途 |
| CN117679505A (zh) * | 2022-09-09 | 2024-03-12 | 中山康方生物医药有限公司 | 药物组合及用途 |
| WO2024163009A1 (en) * | 2023-01-31 | 2024-08-08 | Genentech, Inc. | Methods and compositions for treating urothelial bladder cancer |
| TW202436339A (zh) * | 2023-01-31 | 2024-09-16 | 瑞士商赫孚孟拉羅股份公司 | 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2542256B1 (en) * | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP6595458B2 (ja) * | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| HUE068868T2 (hu) * | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| US20190002563A1 (en) * | 2015-08-17 | 2019-01-03 | Macrogenics, Inc. | Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| GEP20227398B (en) * | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| HRP20210602T1 (hr) * | 2016-06-20 | 2021-05-14 | F-Star Delta Limited | Vezujuće molekule koje vežu pd-l1 i lag-3 |
| US20200148785A1 (en) * | 2017-03-29 | 2020-05-14 | Glycotope (GmbH) | Pd-l1 and ta-muc1 antibodies |
| EP4516809A3 (en) * | 2017-04-05 | 2025-09-03 | F. Hoffmann-La Roche AG | Bispecific antibodies specifically binding to pd1 and lag3 |
| CN110678200B (zh) * | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| US20210115138A1 (en) * | 2018-03-20 | 2021-04-22 | WuXi Biologics Ireland Limited | Novel bispecific pd-1/lag-3 antibody molecules |
-
2020
- 2020-12-18 CN CN202080090186.8A patent/CN114901306A/zh active Pending
- 2020-12-18 IL IL294207A patent/IL294207A/en unknown
- 2020-12-18 JP JP2022538737A patent/JP2023507848A/ja active Pending
- 2020-12-18 US US17/787,793 patent/US20230056230A1/en active Pending
- 2020-12-18 CA CA3165839A patent/CA3165839A1/en active Pending
- 2020-12-18 EP EP20906153.0A patent/EP4081248A4/en active Pending
- 2020-12-18 MX MX2022007790A patent/MX2022007790A/es unknown
- 2020-12-18 KR KR1020227025578A patent/KR20220119694A/ko active Pending
- 2020-12-18 BR BR112022012437A patent/BR112022012437A2/pt unknown
- 2020-12-18 WO PCT/US2020/065873 patent/WO2021133653A1/en not_active Ceased
- 2020-12-18 AU AU2020412595A patent/AU2020412595A1/en active Pending
- 2020-12-22 TW TW109145572A patent/TW202138387A/zh unknown
-
2022
- 2022-06-17 ZA ZA2022/06743A patent/ZA202206743B/en unknown
-
2025
- 2025-09-18 JP JP2025154757A patent/JP2026001028A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507848A5 (https=) | ||
| Reichert et al. | The future of antibodies as cancer drugs | |
| JP6953612B2 (ja) | チェックポイントインヒビター二重特異性抗体 | |
| Shim | One target, different effects: a comparison of distinct therapeutic antibodies against the same targets | |
| JP7720785B2 (ja) | 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント | |
| JP2020501531A5 (https=) | ||
| JP2009541492A5 (https=) | ||
| Hinoda et al. | Monoclonal antibodies as effective therapeutic agents for solid tumors | |
| JP2018524394A5 (https=) | ||
| JP2013529059A5 (https=) | ||
| JP2021510736A5 (https=) | ||
| HRP20241289T1 (hr) | Molekule za vezanje pd-1 i postupci za njihovu uporabu | |
| CA2872226A1 (en) | Humanized pan-her antibody compositions | |
| JP2021525544A5 (https=) | ||
| CN114901306A (zh) | 用于治疗癌症的疗法 | |
| EP4588524A2 (en) | Anti-tigit and anti-pvrig in monotherapy and combination treatments | |
| EP3929213A1 (en) | Anti-pd-l1 antibody and use thereof | |
| CN110997000A (zh) | 用于治疗ErbB-2/ErbB-3阳性肿瘤的抗体 | |
| JP2023548375A (ja) | Ｅｒｂｂ３変異陽性がんを有する対象を治療するための手段及び方法 | |
| MX2015000730A (es) | Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja. | |
| JP2023536086A5 (https=) | ||
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| WO2021058735A1 (en) | Cancer treatment with anti-met antibody compositions | |
| KR20250130296A (ko) | 항-ccr8 항체 및 이의 용도 | |
| JP7726978B2 (ja) | 抗ｃｌｄｎ－１８．２抗体及びその用途 |